Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
- 2.8k Downloads
We report the analysis of CPI-613, the first member of a large set of analogs of lipoic acid (lipoate) we have investigated as potential anticancer agents. CPI-613 strongly disrupts mitochondrial metabolism, with selectivity for tumor cells in culture. This mitochondrial disruption includes activation of the well-characterized, lipoate-responsive regulatory phosphorylation of the E1α pyruvate dehydrogenase (PDH) subunit. This phosphorylation inactivates flux of glycolysis-derived carbon through this enzyme complex and implicates the PDH regulatory kinases (PDKs) as a possible drug target. Supporting this hypothesis, RNAi knockdown of the PDK protein levels substantially attenuates CPI-613 cancer cell killing. In both cell culture and in vivo tumor environments, the observed strong mitochondrial metabolic disruption is expected to significantly compromise cell survival. Consistent with this prediction, CPI-613 disruption of tumor mitochondrial metabolism is followed by efficient commitment to cell death by multiple, apparently redundant pathways, including apoptosis, in all tested cancer cell lines. Further, CPI-613 shows strong antitumor activity in vivo against human non-small cell lung and pancreatic cancers in xenograft models with low side-effect toxicity.
KeywordsCancer Metabolism Mitochondria Lipoic acid PDH
We are grateful to Gregg Semenza and Bob Weinberg for helpful discussions. We thank colleagues, including Pat Hearing, for help early in this project. This work was largely funded by Cornerstone Pharmaceuticals with early support from the Carol M. Baldwin Breast Cancer Research Fund and Stony Brook Biotechnology Center.
Maturo, Gupta, Howell, Schauble, Lem, Piramzadian, Karnik, and Lee are or were employees of Cornerstone Pharmaceuticals, developers of CPI-613. Zachar, Rodriguez, Shorr, and Bingham have a financial interest in Cornerstone Pharmaceuticals.
(MOV 1641 kb)
(MOV 2437 kb)
- 9.Garrett R, Grisham CM (2007) Biochemistry. Thomson Brooks, SouthbankGoogle Scholar
- 15.Sugden MC, Holness MJ (2003) Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol 284:E855–E862Google Scholar
- 21.McFate T, Mohyeldin A, Mohyeldin A, Lu H, Thakar J, Henriquez J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, Zhou S, Califano JA, Jeoun NH, Harris RA, Verma A (2008) Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283:22700–22708PubMedCrossRefGoogle Scholar
- 24.Takeda Y, Perez-Pinzon MA, Ginsberg MD, Sick TJ (2004) Mitochondria consume energy and compromise cellular membrane potential by reversing ATP synthetase activity during focal ischemia in rats. J Cereb Blood Flow Metab 24:986–992Google Scholar
- 30.Bonnet S, Archer SL, Allalunic-Turner J, Harmony A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Mechelas ED (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51PubMedCrossRefGoogle Scholar
- 31.Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, Santarius R, Avis T, Barthrope S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Hunter C, Jenkinson A, Jones D, Kosmidou V, Lugg R, Menzies A, Mironeneko T, Parker A, Perry J, Raine K, Richardson D, Shepherd R, Small A, Smith R, Soloman H, Stephens P, Teague J, Tofts C, Varain J, Webb T, West S, Widaa S, Yates A, Reinhoid W, Weinstein JN, Stratton MR, Futreal PA, Wooster R (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5:2606–2612PubMedCrossRefGoogle Scholar
- 33.Augenlicht LH, Wadler S, Corner G, Richards C, Multani AS, Pathak S, Benson A, Haller D, Heerdt BG (1997) Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: A frequent p53-independent mutation associated with improved outcome in randomized multi-institutional trial. Cancer Res 57:1769–1775PubMedGoogle Scholar